Clinical Trial Update: Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial comparing 0.5 mg ranibizumab with higher doses for clinically significant diabetic macular edema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Philip J. ferrone, M.D. | Conditions: Clinically Significant Diabetic Macular Edema | Phase 1, Phase 2 | Status: COMPLETED